Safusidenib, also known as DS-1001, is a novel selective mutant IDH1 inhibitor. Safusidenib prevents the aberrant conversion of α-ketoglutarate (α-KG) to D-2-hydroxyglutarate (D-2HG). Safusidenib helps reverse tumor-induced epigenetic reprogramming and restores normal cellular differentiation. Safusidenib showedbetter brain penetration, making it particularly promising for gliomas and other central nervous system (CNS) malignancies. Safusidenib is high selectivity for mIDH1 over wild-type IDH1 and IDH2. Safusidenib showed Potent D-2HG suppression in IDH1-mutant tumors, leading to differentiation of glioma cells. Safusidenib demonstrates CNS penetration, distinguishing it from other mIDH1 inhibitors like Ivosidenib (AG-120).
MedKoo Cat#: 124411
Name: Safusidenib free acid
CAS#: 1898206-17-1 (free acid)
Chemical Formula: C25H18Cl3FN2O4
Exact Mass: 534.0316
Molecular Weight: 535.78
Elemental Analysis: C, 56.04; H, 3.39; Cl, 19.85; F, 3.55; N, 5.23; O, 11.94
The following data is based on the product molecular weight 535.78 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
|---|---|---|---|
| 1 mM | 1.15 mL | 5.76 mL | 11.51 mL |
| 5 mM | 0.23 mL | 1.15 mL | 2.3 mL |
| 10 mM | 0.12 mL | 0.58 mL | 1.15 mL |
| 50 mM | 0.02 mL | 0.12 mL | 0.23 mL |
